16.15
Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advan…
Transdermal drug delivery systems or TDDS use patches to release drugs through the skin into systemic circulation at a controlled rate.
These systems benefit drugs with short half-lives or narrow therapeutic indices by maintaining stable plasma levels.
They include monolithic systems—in which drugs are embedded in a polymer matrix—and reservoir systems—in which drugs are stored in a compartment with a rate-controlling membrane.
Mixed systems combine both types, offering an initial controlled release followed by diffusion through the matrix.
Two steps limit the choice of TDDS: diffusion from the patch and skin permeation.
Advantages include noninvasive application, bypassing GI degradation and first-pass metabolism, and good patient compliance.
However, they are unsuitable for high-dose drugs, large molecules, extremely lipophilic or hydrophilic compounds, skin irritants, or drugs heavily metabolized in the skin.
Common examples of transdermal delivery systems include scopolamine and contraceptives like Ortho Evra.
View the full transcript and gain access to JoVE Core videos
Q1: What are the main types of transdermal drug delivery systems?
Transdermal drug delivery systems include three main types: monolithic systems, where drugs are embedded in a polymer matrix; reservoir systems, which store drugs in a compartment separated by a rate-controlling membrane; and mixed systems that combine both approaches. Mixed systems offer an initial rapid release followed by sustained diffusion through the matrix, providing greater control over release profiles.
Q2: How do transdermal patches maintain stable drug levels in the bloodstream?
Transdermal patches release drugs through the skin into systemic circulation at a controlled rate, maintaining stable plasma levels. This controlled delivery is particularly beneficial for drugs with short half-lives or narrow therapeutic indices, as it prevents subtherapeutic or toxic levels. The rate-limiting steps—diffusion from the patch and skin permeation—govern the release kinetics.
Q3: What are the key advantages of transdermal drug delivery over oral administration?
Transdermal delivery is noninvasive and bypasses gastrointestinal degradation and hepatic first-pass metabolism, improving drug bioavailability. It enhances patient compliance through ease of use and reduced dosing frequency, making it ideal for chronic treatments. These features enable precise and sustained drug delivery while minimizing systemic side effects.
Q4: Which drugs are unsuitable candidates for transdermal delivery systems?
Transdermal systems are unsuitable for high-dose drugs, large molecules like proteins or peptides, and compounds that are extremely lipophilic or hydrophilic. Drugs that cause skin irritation or undergo significant metabolism in the skin are also poor candidates. Ideal candidates have low molecular weight, moderate lipophilicity, and high potency.
Q5: What clinical conditions benefit most from transdermal drug delivery?
Transdermal systems excel for chronic treatments requiring stable drug levels, including hormone replacement therapy, pain management, nicotine replacement, contraception, cardiovascular conditions, and neurological disorders. Common examples include scopolamine for motion sickness, Ortho Evra for contraception, and Duragesic for pain management, demonstrating the system's capability for sustained therapeutic delivery.
Q6: How do rate-limiting steps affect transdermal drug delivery?
Two rate-limiting steps control transdermal delivery: diffusion from the patch and skin permeation. These steps determine how quickly and effectively a drug reaches systemic circulation. Understanding these limiting factors is essential for designing effective transdermal systems and predicting drug release profiles.
Q7: Why are mixed transdermal systems preferred for certain drug applications?
Mixed transdermal systems combine monolithic and reservoir designs to offer an initial rapid release followed by sustained diffusion through the matrix. This dual-phase approach provides greater control over release profiles, allowing clinicians to achieve optimal therapeutic outcomes by tailoring the delivery kinetics to specific drug requirements and clinical needs.